GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » DeferredTaxAndRevenue

Vidac Pharma Holding (STU:T9G) DeferredTaxAndRevenue : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Vidac Pharma Holding's current deferred tax and revenue for the quarter that ended in Jun. 2024 was €0.00 Mil.

Vidac Pharma Holding DeferredTaxAndRevenue Historical Data

The historical data trend for Vidac Pharma Holding's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding DeferredTaxAndRevenue Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23
DeferredTaxAndRevenue
- - -

Vidac Pharma Holding Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
DeferredTaxAndRevenue Get a 7-Day Free Trial - - - - -

Vidac Pharma Holding DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vidac Pharma Holding Business Description

Traded in Other Exchanges
N/A
Address
Wenlock Road, 20-22, London, GBR, N1 7GU
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines